EP4735478A1 - Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa - Google Patents

Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa

Info

Publication number
EP4735478A1
EP4735478A1 EP24737768.2A EP24737768A EP4735478A1 EP 4735478 A1 EP4735478 A1 EP 4735478A1 EP 24737768 A EP24737768 A EP 24737768A EP 4735478 A1 EP4735478 A1 EP 4735478A1
Authority
EP
European Patent Office
Prior art keywords
amino acid
seq
acid sequence
cdr
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP24737768.2A
Other languages
German (de)
English (en)
Inventor
Florian Klein
Jan RYBNIKER
Alexander Simonis
Christoph KREER
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitaet zu Koeln
Original Assignee
Universitaet zu Koeln
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitaet zu Koeln filed Critical Universitaet zu Koeln
Publication of EP4735478A1 publication Critical patent/EP4735478A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La présente divulgation concerne des anticorps ou des fragments de liaison à l'antigène de ceux-ci dirigés contre Pseudomonas aeruginosa, des compositions pharmaceutiques comprenant de tels anticorps ou des fragments de liaison à l'antigène de ceux-ci, des kits comprenant de tels anticorps ou fragments de liaison à l'antigène de ceux-ci, et les anticorps ou fragments de liaison à l'antigène de ceux-ci, les compositions pharmaceutiques et les kits pour une utilisation en tant que médicament, et dans le traitement ou la prévention d'une maladie provoquée par Pseudomonas aeruginosa. La présente divulgation concerne en outre des méthodes de traitement, de prévention ou de réduction de la gravité d'une infection par Pseudomonas aeruginosa, et des acides nucléiques codant pour de tels anticorps ou fragments de liaison à l'antigène de ceux-ci, des vecteurs d'expression comprenant de tels acides nucléiques, des cellules hôtes comprenant de tels acides nucléiques ou vecteurs d'expression, et des procédés de production de tels anticorps ou fragments de liaison à l'antigène de ceux-ci.
EP24737768.2A 2023-06-28 2024-06-27 Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa Pending EP4735478A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP23182149 2023-06-28
PCT/EP2024/068217 WO2025003381A1 (fr) 2023-06-28 2024-06-27 Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa

Publications (1)

Publication Number Publication Date
EP4735478A1 true EP4735478A1 (fr) 2026-05-06

Family

ID=87035846

Family Applications (1)

Application Number Title Priority Date Filing Date
EP24737768.2A Pending EP4735478A1 (fr) 2023-06-28 2024-06-27 Neutralisation d'anticorps monoclonaux humains contre p. aeruginosa

Country Status (8)

Country Link
EP (1) EP4735478A1 (fr)
KR (1) KR20260048372A (fr)
CN (1) CN121773129A (fr)
AR (1) AR133129A1 (fr)
AU (1) AU2024307442A1 (fr)
IL (1) IL325603A (fr)
TW (1) TW202515902A (fr)
WO (1) WO2025003381A1 (fr)

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
ATE221379T1 (de) 1991-05-01 2002-08-15 Jackson H M Found Military Med Verfahren zur behandlung infektiöser respiratorischer erkrankungen
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
AU2063197A (en) 1996-03-04 1997-09-22 Massachusetts Institute Of Technology Materials and methods for enhancing cellular internalization
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
ES2236832T3 (es) 1997-01-16 2005-07-16 Massachusetts Institute Of Technology Preparacion de particulas para inhalacion.
AU7266698A (en) 1997-04-30 1998-11-24 Enzon, Inc. Polyalkylene oxide-modified single chain polypeptides
CA2336139C (fr) 1998-06-24 2008-10-14 Advanced Inhalation Research, Inc. Grandes particules poreuses emises par un inhalateur
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
EP1353688B1 (fr) 2001-01-26 2006-12-06 MCW Research Foundation, Inc. Procede et compositions d'immunisation avec l'antigene v de i pseudomonas /i
JP2007534631A (ja) 2003-10-28 2007-11-29 ノボ　ノルディスク　アクティーゼルスカブ ラミニン−５γ２結合性ペプチド、その関連組成物およびその使用
AU2009203426C1 (en) 2008-01-10 2012-05-31 Shionogi & Co., Ltd. Antibody directed against PcrV
DK2407537T6 (en) 2009-03-11 2015-07-27 Shionogi & Co PcrV HUMANIZED ANTIBODY WITH ACTIVITY ANTIPSEUDOMONAL
US10597439B2 (en) * 2011-11-07 2020-03-24 Medimmune Limited Combination therapies using anti-pseudomonas PSL and PCRV binding molecules
BR112021023335A2 (pt) 2019-06-11 2022-01-04 Regeneron Pharma Anticorpos recombinante isolado ou seu fragmento de ligação ao antígeno e monoclonal isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, método de diminuição do risco de adquirir infecção por p. aeruginosa, e, métodos de diminuição da carga bacteriana em um sujeito com uma infecção por p. aeruginosa, de aumento da sobrevida ou da probabilidade de sobrevida de um sujeito que sofre de infecção por p. aeruginosa ou de um sujeito que corre risco de infecção por p. aeruginosa, para melhorar ou reduzir a gravidade, a duração ou a frequência de ocorrência de pelo menos um sintoma de uma infecção por p. aeruginosa, para aumentar a sobrevida ou a probabilidade de sobrevida de um sujeito que sofre de fibrose cística
EP3997121A4 (fr) * 2019-07-09 2024-03-27 Beijing SoloBio Genetechnology Company Ltd. Anticorps reconnaissant spécifiquement pcrv de pseudomonas et leurs utilisations

Also Published As

Publication number Publication date
TW202515902A (zh) 2025-04-16
AU2024307442A1 (en) 2026-02-19
KR20260048372A (ko) 2026-04-09
WO2025003381A1 (fr) 2025-01-02
AR133129A1 (es) 2025-08-27
IL325603A (en) 2026-02-01
CN121773129A (zh) 2026-03-31

Similar Documents

Publication Publication Date Title
US11203633B2 (en) Polynucleotides encoding antibodies or antigen binding fragments thereof that bind pseudomonas perv
JP5781765B2 (ja) シュードモナス・エルギノーサ（ＰｓｅｕｄｏｍｏｎａｓＡｅｒｕｇｉｎｏｓａ）のＰｃｒＶ抗原に対する抗体
US20150284450A1 (en) Combination therapies using anti-pseudomonas psl and pcrv binding molecules
US20230242624A1 (en) HUMAN ANTIBODIES AGAINST SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS-2 (SARS-CoV-2)
EP4157455A1 (fr) Anticorps neutralisants contre le coronavirus associé au sars
JP2011505381A5 (fr)
RU2758008C2 (ru) Анти-il-5 антитела
WO2024175802A2 (fr) Anticorps neutralisant le sars-cov-2
AU2024307442A1 (en) Neutralizing human monoclonal antibodies against p. aeruginosa
US20250154230A1 (en) Neutralizing antibodies against sars-related coronavirus
EP4190810A1 (fr) Neutralisation d'anticorps contre le coronavirus apparenté au virus du sras
EP4484445A1 (fr) Anticorps neutralisants du hcmv
CN118660905A (zh) 针对sars相关冠状病毒的中和抗体
TW202313693A (zh) 一種cdc平臺抗體
TW202521582A (zh) 靶向ActRIIA及ActRIIB之抗體
CN116724049A (zh) 针对sars相关冠状病毒的中和抗体
CN121399160A (zh) 靶向ccr2的抗体

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: UNKNOWN

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20260127

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR